CD274 and non-small cell lung carcinoma: Thus, regarding both endpoints, for NSCLC patients with PD-L1 TPS ≥50% treated with first-line PD-L1 inhibitor monotherapy, a high ALI score (>18) was able to distinguish a favorable subset with outcomes similar to those who received chemo-immunotherapy (Figure 2D and E).